Publications

1.      Doecke JD, Chekouo T, Stingo FC, and Do K-A. miRNA target gene identification: sourcing miRNA-target gene relationships for the analyses of TCGA Illumina miSeq and RNA-Seq Hiseq platform data. International Journal of Human Genetics 14(1):17-22, 4/2014.

2.      Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer . Ann Oncol 25(6):1122-7, 6/2014. e-Pub 3/2014. PMCID: PMC4037860.

3.      Blanco E, Sangai T, Wu S, Hsiao A, Ruiz-Esparza GU, Gonzalez-Delgado CA, Cara FE, Granados-Principal S, Evans KW, Akcakanat A, Wang Y, Do KA, Meric-Bernstam F, Ferrari M. Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway. Mol Ther 22(7):1310-9, 7/2014. e-Pub 2/2014. PMCID: PMC4088997.

4.      Meric-Bernstam F, Akcakanat A, Chen H, Sahin A, Tarco E, Carkaci S, Adrada BE, Singh G, Do KA, Garces ZM, Mittendorf E, Babiera G, Bedrosian I, Hwang R, Krishnamurthy S, Symmans WF, Gonzalez-Angulo AM, Mills GB. Influence of Biospecimen Variables on Proteomic Biomarkers in Breast Cancer. Clin Cancer Res 20(14):3870-83, 7/2014. e-Pub 6/2014. PMCID: PMC4112583.

5.      Pande M, Bondy ML, Do KA, Sahin AA, Ying J, Mills GB, Thompson PA, Brewster AM. Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival. Breast Cancer Res Treat 147(2):381-7, 9/2014. e-Pub 8/2014. PMCID: PMC4174407.

6.      Hassan B, Akcakanat A, Sangai T, Evans KW, Adkins F, Eterovic AK, Zhao H, Chen K, Chen H, Do KA, Xie SM, Holder AM, Naing A, Mills GB, Meric-Bernstam F. Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. Oncotarget 5(18):8544-57, 9/2014. e-Pub 8/2014. PMCID: PMC4226703.

7.      Shirazi F, Farmakiotis D, Yan Y, Albert N, Do K-A,. Diet modification and Metformin have a beneficial cial effect in a model of obesity and mucormycosis. PLoS One 9(9), 9/2014. PMCID: PMCPMC4182538.

8.      Tam CS, O'Brien S, Plunkett W, Wierda W, Ferrajoli A, Wang X, Do KA, Cortes J, Khouri I, Kantarjian H, Lerner S, Keating MJ. Life After FCR: Outcomes of patients with chronic lymphocytic leukemia who progress after frontline treatment with Fludarabine, Cyclophosphamide and Rituximab. Blood 124(20):3059-64, 11/2014. e-Pub 10/2014. PMCID: PMC4231417.

9.      Gorlov IP, Yang JY, Byun J, Logothetis C, Gorlova OY, Do KA, Amos C. How to get the most from microarray data: advice from reverse genomics. BMC Genomics 15:223, 2014. e-Pub 3/2014. PMCID: PMC3997969.

10.  Rembach A, Stingo FC, Peterson C, Vannucci M, Do K-A. Bayesian graphical network analyses reveal complex biological interactions specific to Alzheimer's disease. J Alzheimer's Disease. In Press.

11.  Zhang L, Baladandayuthapani V, Mallick BK, Thompson PA, Bondy ML, Do K-A. Bayesian hierarchical structured variable selection methods with application to MIP studies in breast cancer. J Royal Stat Soc, Series C, Volume 63, Issue 4, 595-620, August 2014.

12.  Chekouo T, Stingo FC, Doecke JD, Do K-A. Incorporating microRNA regulatory network and pathways: A Bayesian graphical approach to the selection of miRNAs and genes with censored outcomes. Biometrics. In Press.

13.  Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do K-A, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC vs. the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer. Ann Oncol. In Press.

14.  Ha MJ, Baladandayuthapani, Do K-A. Prognostic gene signature identification using causal structural learning: applications in kidney cancer. Cancer Informatics. In Press.

15.  Gonzalez-Angulo AM , Krop I, Akcakanat A, Chen H, Liu S, Li Y, Culotta SK, Tarco M, Piha-Paul S, Moulder-Thompson S, Velez-Bravo V, Sahin A, Doyle LA, Do K-A, Winer EP, Mills GB, Kurzrock R, Meric-Bernstam F. SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer. J Natl Cancer Inst. In Press.

16.  Pasqualini R , Millikan RE, Christianson DR, Cardó-Villa M, Driessen WHP, Giordano RJ, Hajitou A, Hoang AG, Wen S, Barnhart KF, Baze WB, Marcott VD, Hawke DH, Do K-A, Navone NM, Efstathiou E, Troncoso P, Lobb RR, Logothetis CJ, Arap W. Targeting the Interleukin-11 Receptor in Metastatic Prostate Cancer: A First-in-Man Study. Cancer. In Press.

17.    Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, Miller TW, Arteaga CL, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res 18(20):5816-28, 10/2012. e-Pub 8/2012. PMCID: PMC3772348.

18.    Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez-MacGregor M, Tsavachidis S, Meric-Bernstam F, Do KA, Hortobagyi GN, Thompson PA, Mills GB, Bondy ML, Blumenschein GR. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer 119(1):7-15, 1/2013. e-Pub 6/2012. PMCID: PMC3461089.

19.     Holder AM, Gonzalez-Angulo AM, Chen H, Akcakanat A, Do KA, Fraser Symmans W, Pusztai L, Hortobagyi GN, Mills GB, Meric-Bernstam F. High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Breast Cancer Res Treat 137(1):319-27, 1/2013. e-Pub 12/2012. PMCID: PMC3556743.

20.    Wang W, Baladandayuthapani V, Morris JS, Broom BM, Manyam G, Do KA. iBAG: integrative Bayesian analysis of high-dimensional multi-platform genomics data. Bioinformatics 29(2):149-59, 1/2013. e-Pub 11/2012. PMCID: PMC3546799.

21.     Pande M, Thompson PA, Do KA, Sahin AA, Amos CI, Frazier ML, Bondy ML, Brewster AM. Genetic variants in the vitamin D pathway and breast cancer disease-free survival. Carcinogenesis 34(3):587-94, 3/2013. e-Pub 11/2012. PMCID: PMC3581599.

22.    Leon-Novelo LG, Mueller P, Arap W, Kolonin M, Sun J, Pasqualini R, Do KA. Semiparametric Bayesian Inference for Phage Display Data. Biometrics 69(1):174-83, 3/2013. e-Pub 1/2013. PMCID: PMC3622196.

23.     Gonzalez-Angulo AM, Liu S, Chen H, Chavez-Macgregor M, Sahin A, Hortobagyi GN, Mills GB, Do KA, Meric-Bernstam F. Functional Proteomics Characterization of Residual Breast Cancer After Neoadjuvant Systemic Chemotherapy. Ann Oncol 24(4):909-16, 4/2013. e-Pub 11/2012. PMCID: PMC3603436.

24.      Murray JL, Thompson P, Yoo SY, Do KA, Pande M, Zhou R, Liu Y, Sahin AA, Bondy ML, Brewster AM. Prognostic Value of Single Nucleotide Polymorphisms of Candidate Genes Associated with Inflammation in Early Stage Breast Cancer. Breast Cancer Res Treat 138(3):917-24, 4/2013. e-Pub 3/2013. PMCID: PMC3746974.

25.    Leon-Novelo LG, Mueller P, Arap W, Sun J, Pasqualini R, Do KA. Bayesian decision theoretic multiple comparison procedures: an application to phage display data. Biom J 55(3):478-89, 5/2013. e-Pub 12/2012. PMCID: PMC3840910.

26.     Bayraktar S, Thompson PA, Yoo SY, Do KA, Sahin AA, Arun BK, Bondy ML, Brewster AM. The Relationship Between Eight GWAS-Identified Single Nucleotide Polymorphisms and Primary Breast Cancer Outcomes. Oncologist. e-Pub 5/2013. PMCID: PMC3662839.

27.     Sohn J, Do KA, Liu S, Chen H, Mills GB, Hortobagyi GN, Meric-Bernstam F, Gonzalez-Angulo AM. Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy. Ann Oncol 24(10):2522-6, 10/2013. e-Pub 8/2013. PMCID: PMC3784335.

28.    Wang W, Baladandayuthapani V, Holmes CC, Do KA. Integrative network-based Bayesian analysis of diverse genomics data. BMC Bioinformatics 14 Suppl 13:S8, 2013. e-Pub 10/2013. PMCID: PMC3849715.

29.    Liu Y, Zhou R, Baumbusch LO, Tsavachidis S, Brewster AM, Do KA, Sahin A, Hortobagyi GN, Taube JH, Mani SA, Aarøe J, Wärnberg F, Børresen-Dale AL, Mills GB, Thompson PA, Bondy ML. Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer. Breast Cancer Res Treat 143(1):189-201, 1/2014. e-Pub 12/2013. PMCID: PMC3993091.

30.    Chavez-Macgregor M, Liu S, De Melo-Gagliato D, Chen H, Do KA, Pusztai L, Fraser Symmans W, Nair L, Hortobagyi GN, Mills GB, Meric-Bernstam F, Gonzalez-Angulo AM. Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. Cancer Epidemiol Biomarkers Prev 23(2):316-23, 2/2014. e-Pub 12/2013. PMCID: PMC3946290.

31.    Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17(5):1082-9, 3/2011. e-Pub 1/2011. PMCID: PMC3048924.

32.    Hernandez-Aya LF, Chavez-Macgregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, Sahin AA, Do KA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 29(19):2628-34, 7/2011. e-Pub 5/2011. PMCID: PMC3139370.

33.     Raghav KP, Hernandez-Aya LF, Lei X, Gregor MC, Meric-Bernstam F, Buchholz TA, Sahin A, Do KA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer. e-Pub 8/2011. PMCID: PMC3217101.

34.     Brewster AM, Thompson P, Sahin AA, Do K, Edgerton M, Murray JL, Tsavachidis S, Zhou R, Liu Y, Zhang L, Mills G, Bondy M. Copy number imbalances between screen and symptom-detected breast cancers and impact on disease-free survival. Cancer Prev Res (Phila) 4(10):1609-16, 10/2011. e-Pub 7/2011. PMCID: PMC3188338.

35.     Heymach JV, Shackleford TJ, Tran HT, Yoo SY, Do KA, Wergin M, Saintigny P, Vollmer RT, Polascik TJ, Snyder DC, Ruffin MT, Yan S, Dewhirst M, Kunnumakkara AB, Aggarwal BB, Demark-Wahnefried W. Effect of low-fat diet on plasma levels of NF-{kappa}B-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer. Cancer Prev Res (Phila) 4(10):1590-8, 10/2011. e-Pub 7/2011. PMCID: PMC3438697.

36.    Barnhart KF, Christianson DR, Hanley PW, Driessen WH, Bernacky BJ, Baze WB, Wen S, Tian M, Ma J, Kolonin MG, Saha PK, Do KA, Hulvat JF, Gelovani JG, Chan L, Arap W, Pasqualini R. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med 3(108):108ra112, 11/2011. PMCID: PMC3666164.

37.    Staquicini FI, Cardo-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH, Wallace MJ, O'Connell DJ, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Setubal JC, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Sidman RL, Pasqualini R, Arap W. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A 108(46):18637-42, 11/2011. e-Pub 11/2011. PMCID: PMC3219136.

38.     Wierda WG, O'Brien S,Wang X, Faderl S, Ferrajoli A, Do K-A, Garcia-Manero G,Cortes J, Thomas D, Koller C, Burger J, Lerner S, Schlette E, Abruzzo L, Kantarjan H, Keating M. A multivariate model for time-to-first treatment in patients with chronic lymphocytic leukemia. JCO 29:4088-95, 2011.

39.    Thompson PA, Brewster AM, Do K-A, Baladandayuthapani V, Broom BM, Edgerton ME, Hahn KM, Murray JL, Sahin A, Tsavachidis S, Wang Y, Zhang L, Hortobagyi GN, Mills GB, Bondy ML. Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. PLoS One 6(8):e23543, 2011. e-Pub 8/2011. PMCID: PMC3155554.

40.    Gonzalez-Angulo AM, Iwamoto T, Liu S, Chen H, Do KA, Hortobagyi GN, Mills GB, Meric-Bernstam F, Symmans WF, Pusztai L. Gene expression, molecular class changes and pathway analysis after neoadjuvant systemic therapy for breast cancer. Clin Cancer Res 18(4):1109-19, 2/2012. e-Pub 1/2012. PMCID: PMC3288822.

41.    Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F, Gonzalez-Angulo AM, Rashid A, Crosby K, Dong M, Phan AT, Wolff RA, Gupta S, Mills GB, Yao J. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res 18(6):1777-89, 3/2012. PMCID: PMC3307149.

42.   Meric-Bernstam F, Chen H, Akcakanat A, Do KA, Lluch A, Hennessy BT, Hortobagyi GN, Mills GB, Gonzalez-Angulo AM. Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Res 14(5):R138. e-Pub 10/2012.

43.              Bonato V, Baladandayuthapani V, Broom BM, Sulman EP, Aldape KD, Do KA. Bayesian ensemble methods for survival prediction in gene expression data. Bioinformatics 27(3):359-67, 2/2011. e-Pub 12/2010. PMCID: PMC3031034.

44.              Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17(5):1082-9, 3/2011. e-Pub 1/2011. PMCID: PMC3048924.

45.              Hernandez-Aya LF, Chavez-Macgregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, Sahin AA, Do KA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 29(19):2628-34, 7/2011. e-Pub 5/2011. PMCID: PMC3139370.

46.              Raghav KP, Hernandez-Aya LF, Lei X, Gregor MC, Meric-Bernstam F, Buchholz TA, Sahin A, Do KA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer. e-Pub 8/2011.

47.              Brewster AM, Thompson P, Sahin AA, Do KA, Edgerton M, Murray JL, Tsavachidis S, Zhou R, Liu Y, Zhang L, Mills G, Bondy M. Copy number imbalances between screen and symptom-detected breast cancers and impact on disease-free survival. Cancer Prev Res (Phila) 4(10):1609-16, 10/2011. e-Pub 7/2011. PMCID: PMC3188338.

48.              Heymach JV, Shackleford TJ, Tran HT, Yoo SY, Do KA, Wergin M, Saintigny P, Vollmer RT, Polascik TJ, Snyder DC, Ruffin MT, Yan S, Dewhirst M, Kunnumakkara AB, Aggarwal BB, Demark-Wahnefried W. Effect of low-fat diet on plasma levels of NF-{kappa}B-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer. Cancer Prev Res (Phila) 4(10):1590-8, 10/2011. e-Pub 7/2011.

49.              Wierda WG, O’Brien S,Wang X, Faderl S, Ferrajoli A, Do K-A, Garcia-Manero G,Cortes J, Thomas D, Koller C, Burger J, Lerner S, Schlette E, Abruzzo L, Kantarjan H, Keating M. A multivariate model for time-to-first treatment in patients with chronic lymphocytic leukemia. JCO 29:4088-95, 2011.

50.              Thompson PA, Brewster AM, Do K-A, Baladandayuthapani V, Broom BM, Edgerton ME, Hahn KM, Murray JL, Sahin A, Tsavachidis S, Wang Y, Zhang L, Hortobagyi GN, Mills GB, Bondy ML. Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. PLoS One 6(8):e23543, 2011. e-Pub 8/2011. PMCID: PMC3155554.

51.              Staquicini F, Cardo-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu S-M, Botz GH, Wallace MJ, O’Connell DJ, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Setubal JC, Cahill DJ, Troncoso P,  Do K-A, Logothetis CJ, Sidman RL,  Pasqualini R, Arap W.  Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. PNAS. In Press, November 2011. www.pnas.org/cgi/doi/10.1073/pnas.1114503108

52.              Barnhart KF, Christianson DR, Hanley PW, Driessen WH, Bernacky BJ, Baze BW, Wen S, Tian M, Ma J, Kolonin MG, Saha PK,  Do K-A, Hulvat JF,  Gelovani JG,  Chan L, Arap W, Pasqualini R. Targeting white adipose tissue in obese monkeys results in weight loss and improved insulin resistance. Science Translational Medicine. In Press. November 2011, Vol 3 (108). http://stm.sciencemag.org/content/3/108/108ra112.full.pdf

53.              Zhang S, Müller P, Do KA. A Bayesian Semiparametric Survival Model with Longitudinal Markers. Biometrics 66(2):435-43, 6/2010. e-Pub 6/2009. PMCID: PMC3045702.

54.              Efstathiou E, Abrahams NA, Tibbs RF, Wang X, Pettaway CA, Pisters LL, Mathew PF, Do KA, Logothetis CJ, Troncoso P. Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification. Eur Urol 57(6):1030-8, 6/2010. e-Pub 10/2009. PMCID: PMC2962710.

55.              Yi M, Hunt KK, Arun BK, Bedrosian I, Barrera AG, Do KA, Kuerer HM, Babiera GV, Mittendorf EA, Ready K, Litton J, Meric-Bernstam F. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila) 3(8):1026-34, 8/2010. e-Pub 7/2010.

56.              Luyimbazi D, Akcakanat A, McAuliffe PF, Zhang L, Singh G, Gonzalez-Angulo AM, Chen H, Do KA, Zheng Y, Hung MC, Mills GB, Meric-Bernstam F. Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer. Mol Cancer Ther 9(10):2770-84, 10/2010. e-Pub 9/2010. PMCID: PMC2965451.

57.              Broom BM, Sulman EP, Do KA, Edgerton ME, Kenneth D. Aldape. Bagged Gene Shaving for the Robust CLustering of High Throughput Data. Int J Bioinform Res Appl 6(4):326-43, 2010.

58.              Lin YX, Baladandayuthapani V, Bonato V, Do KA. Estimating shared copy number aberrations for array CGH data: the linear-median method. Cancer Inform 9:229-49, 2010. e-Pub 10/2010. PMCID: PMC2978932.

59.              Ravoori M, Czaplinska AJ, Sikes C, Han L, Johnson EM, Qiao W, Ng C, Cody DD, Murphy WA, Do KA, Navone NM, Kundra V. Quantification of mineralized bone response to prostate cancer by noninvasive in vivo microCT and non-destructive ex vivo microCT and DXA in a mouse model. PLoS One 5(3):e9854, 2010. e-Pub 3/2010. PMCID: PMC2847943.

60.              Liu Y, Scheurer ME, El-Zein R, Cao Y, Do KA, Gilbert M, Aldape KD, Wei Q, Etzel C, Bondy ML. Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev 18(1):204-14, 1/2009.

61.              Kim J, Jonasch E, Alexander A, Short JD, Cai S, Wen S, Tsavachidou D, Tamboli P, Czerniak BA, Do KA, Wu KJ, Marlow LA, Wood CG, Copland JA, Walker CL. Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res 15(1):81-90, 1/2009.

62.              Gregório SP, Sallet PC, Do KA, Lin E, Gattaz WF, Dias-Neto E. Polymorphisms in genes involved in neurodevelopment may be associated with altered brain morphology in schizophrenia: preliminary evidence. Psychiatry Res 165(1-2):1-9, 1/2009. e-Pub 12/2008.

63.              Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol 27(10):1637-43. e-Pub 2/2009.

64.              Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst 101(5):306-20. e-Pub 2/2009.

65.              Mandelin J, Lin EC, Hu DD, Knowles SK, Do KA, Wang X, Sage EH, Smith JW, Arap W, Pasqualini R. Extracellular and intracellular mechanisms that mediate the metastatic activity of exogenous osteopontin. Cancer 115(8):1753-64, 4/2009.

66.              Montero AJ, Diaz-Montero CM, Millikan RE, Liu J, Do KA, Hodges S, Jonasch E, McIntyre BW, Hwu P, Tannir N. Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survival. Ann Oncol 20(10):1682-7, 10/2009. e-Pub 6/2009.

67.              Jeong J, Vannucci M, Do K-A , Broom BM, Kim S, Sha N, Tadesse M, Tan K, Pusztai L (2008). Gene selection for the identification of biomarkers in high -throughput data. In Bayesian Modeling in Bioinformatics , Dey DK, Ghosh S, Mallick B (Eds), Chapman & Hall / CRC press.

68.              McDonnell T, Chari N, Cho-Vega JH, Troncoso P, Wang X, Bueso-Ramos CE, Brisbay S, Lopez R, Prendergast G, Logothetis C, Do K-A . (2008) Biomarker Expression Patterns that Correlate with High Grade Features in Treatment Naive, Organ-Confined Prostate Cancer. BMC Medical Genomics , Jan 31, online publication.

69.              Kuwai T, Nakamura T, Sasaki T, Kitadai Y, Kim J-S, Langley RR, Fan D, Wang X, Do K-A , Kim S-J, Fidler IJ (2008). Targeting the EGFR, VEGFR, PDGFR o n colon cancer cells and stromal cells is required for therapy, Clinical and Experimental Metastasis , 25(4): 477--489.

70.              Lin S-H, Lee Y-C, Choueiri MB, Wen S, Matthew P, Ye X, Do K-A , Kim J, Tu S-M, Yu-Lee L-Y, Logothetis CJ. Soluble forms of ErbB3 in bone marrow and plasma of men with prostate cancer (2008). Clinical Cancer Research , 16(12):2615--2622.

71.              Ji Y, Yin G, Tsui K-W, Kolonin MG, Sun J, Arap W, Pasqualini R, Do K-A (2007). Bayesian mixture models for complex high-dimensional count data in phage display experiments. Journal of the Royal Statistical Society, Series C - Applied Statistics , 56(2):1-14.

72.              Do K-A , McLachlan GJ, Bean R, Wen S (2007). Gene shaving versus mixture models for the clustering of microarray gene expression data. Cancer Informatics , 2:25-43.

73.              Broom BM, Do K-A (2007). Statistical methods for biomarker discovery using mass spectrometry. Statistical Methodology in the Biomedical Sciences: State of the Art and Future Directions , edited by Atanu Biswas, Sujay Datta, Jason Fine, Mark Segal, Wiley Publishers.

74.              Brewster A, Do K-A , Thompson PA, Hahn KM, Sahin A, Cao Y, Stewart M, Murray J, Hortobagyi GN, Bondy M (2007). The relationship between epidemiological risk factors and breast cancer recurrence. JCO, 25(28):4438--4444.

75.              Cho-Vega JH, Tsavachidis S, Do K-A , Medeiros LJ, Troncoso P, Nakagama J, McDonnell TJ. Dicarbonyl/L-Xylulose Reductase: A potential biomarker identified by laser capture microdissection - micro serial analysis of gene expression of human prostate adenocarcinoma (2007). Cancer Epidemiology, Biomarkers & Prevention , 16(12):2615-2622.

76.              Lin S-H, Lee Y-C, Choueiri MB, Wen S, Matthew P, Ye X, Do K-A , Kim J, Tu S-M, Yu-Lee L-Y, Logothetis CJ. Soluble forms of ErbB3 in bone marrow and plasma of men with prostate cancer (2007). Clinical Cancer Research:2615-2622.

77.              Tsimberidou A-M, Wen S, O'Brien S, McLaughlin P, Wierda WG, Ferrajoli A, Faderl S, Manning J, Lerner S, Mai C, Rodriguez AM, Hess M, Do K-A , Freireich EJ, Kantarjan H, Medeiros LJ, Keating MJ (2007). Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2126 patients: 20 years of experience at M.D. Anderson Cancer Center. JCO , 25(29):4648--4656.

78.              Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do K-A , Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjan H, Keating M (2007). Prognostic nomogram for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood , 109:4679--4685.

79.              Guindani M, Do K-A , Muller P, Morris J. (2006). Bayesian mixture models for gene expression and protein profiles. In Bayesian Inference for Gene Expression and Proteomics , Cambridge University Press, pp. 238-253.

80.              Wang J, Do K-A , Wen S, Tsavachidis S, McDonnell TJ, Logothetis C, Coombes KR (2006). Merging microaray data, robust feature selection, and predicting prognosis in prostate cancer. Cancer Informatics , 2:87-97.

81.              Albitar M, Johnson MM, Do K-A , Day A, Jilani I, Pierce S, Estey E, Kantarjan H, Keating M, Verstovsek S, O'Brien S, Giles FJ (2007). Levels of soluble HLA-I and beta2M in patients with acute myloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy. Leukemia , 21(3):480-488.

82.              Efstathiou E, Troncoso P, Wen S, Do K-A , Chansangavej C, Pettaway CA, McDonnell TJ, Logothetis CJ (2007). Initial modulation of the tumor microenvironment accounts for Thalidomide efficacy in prostate cancer. Clinical Cancer Research , 13(4):1224-1231.

83.              Wu X, Gu J, Dong Q, Huang M, Do K-A , Hong WK, Spitz MR (2006). Joint efect of mutagen sensitivity and insulin-like growth factors in predicting the risk of developing secondary primary tumors and tumor recurrence in patients with head and neck cancer. ClinCancer Res , 12(23):7194-7201.

84.              Esmaeli B, Amin S, Valero V, Adinin R, Arbuckle R, Banay R, Do K-A , Rivera E (2006). Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving Docetaxel. JCO 24(22): 3619-3622.

85.              Mao S, Daliani D, Wang X, Do K-A , Thall PF, Perez CA, Brown MA, Logothetis CJ, Kim J (2007). Randomized, double-blind, placeb o-controlled trial of IM862 in patients with relapsed prostate cancer: a platform for new drug screening. To appear, Clinical Cancer Research .

86.              Kundra V, Ng CS, Ma J, Bankson JA, Price RE, Cody DD, K-A Do , Sikes CR, Erwin WD, Han L, Navone NM (2007). In vivo imaging of prostate cancer involving bone in a mouse model. Prostate} 67(1):50-60.

87.              Busby JE, Kim SJ, Yazici S, Nakamura T, Kim JS, He J, Maya M, Wang X, Do K-A , Fan D, Fidler IJ (2006). Therapy of multidrug resistant human prostate tumors in the prostate of nude mice by simultaneous targeting of the epidermal growth factor receptor and vascular endothelial growth factor receptor on tumor-associated endothelial cells. The Prostate , 66:1788-1798.

88.              Kim SJ, Uehara H, Yazici S, Busby JE, Nakamura T, He J, Maya M, Logothetis C, Mathew P, Wang X, Do K-A , Fan D, Fidler IJ (2006). Targeting platelet-derived growth factor receptor on endothelial cells of multi-drug resistant prostate cancer. JNCI , 98(11):783-793.

89.              Wierda WG, O'Brien S, Faderl S, Ferrajoli A, Wang X, Do K-A , Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating M (2006). A retrospective comparison of three sequential groups of relapsed/refractory patients with ch ronic lymphocytic leukemia treated with Fludarabine-based regimens. Cancer , 106}(2):337-345.

90.              Tannir N, Jonasch E, Pagliaro LC, Matthew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do K-A , Lin SH, Tu S-M (2006). A pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer, 107(3):497-505.

91.              Spiess PE, Lee AK, Leibovici D, Wang X, Do K-A , Pisters LL (2006). Pre-salvage PSA and PSA doubling time as predictors of biochemical failure in patients treated with salvage cryotherapy. Cancer , 107}(2):275-280.

92.              Tsimberidou A-M, O'Brien S, Khouri I, Gile FJ, Kantarjian HM, Champlin R, Wen S, Do K-A , Smith SC, Lerner S, Freireich EJ, Keating MJ (2006). Clinical outcomes and prosnostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunothe rapy with or without stem cell transplantation. Journal of Clinical Oncology , 24:2343-2351.

93.              Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do K-A , Lerner S, Keating MJ (2006). Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with Rituximab with or without chemotherapy or chemotherapy alone. Cancer , 107:125-135.

94.              Kolonin MG, Bover L, Sun J, Do K-A , Zurita AJ, Lahdenranta J, Cardo-Vila M, Giordano RJ, Jaalouk DE, Ozawa MG, Moya CA, Souza GR, Staquicini FI, Kunyiasy A, Scudiero DA, Holbeck SL, Sausville EA, Arap W, Pasqualini R (2006). Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. Cancer Research , 66:34-40.

95.              Kolonin MG, Sun J, Do K-A , Vidal CI, Ji Y, Baggerly KA, Arap W, Pasqualini R (2006). Synchronous selection of homing peptides for multiple tissues by in vivo display. Federation of the American Society for Experimental Biology Journal , 20}(2):979-981.

96.              Spiess PE, Kassouf W, Brown G, Highshaw R, Wang X, Do K-A , Kamat AM, Czerniak B, Dinney CPN, Grossman HB (2006). Immediate versus staged urethrectomy in patients at high-risk of urethral recurrence: Is there a benefit to either approach? Urology , 67:466-471.

97.              Soliman AS, Wang X, Stanley J-D, El-Ghawalby N, Bondy ML, Ezzat F, Soultan A, Abdel-Wahab M, Fathy O, Ebidi G, Abdel-Karim N, Do K-A, Levin B, Hamilton SR, Abruzzese JL (2006). Geographical clustering of pancreatic cancers in the Northeast Nile Delta region of Egypt. Archives of Environmental Contamination and Toxicology , 51:142-148.

98.              Rosser CJ, Kamat AM, Babaian RJ, Wang X, Do K-A , Naya Y, Hoover DC, Troncoso P, Sanches-Ortiz RF, Pisters LL (2006). Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with radical prostatectomy. Urology , 67(4): 769-773.

99.              Rosser CJ, Kamat AM, Wang X, Do K-A , Sanchez-Ortiz RF, Kuban DA, Lee AK, Cheung R, Chichakli R, Pisters LL (2005). Is patien t age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate cancer? Urology , 66(2):327-331.

100.          Faderl S, Do K-A , Johnson MM, Aguilar C, Thomas D, Dey A, Keating M, O'Brien S, Jilani I, Ferrajoli A, Giles FJ, Kantarjian H M, Albitar M (2005). Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia (ALL). Blood , 106(13):4303-4307.

101.          Strom SS, Wang X, Pettaway CA, Yamamura Y, Do K-A, Troncoso P, Babaian RJ, Logothetis CJ (2005). Obesity, weight gain, and risk of biochemical filure among prostate cancer patients following prostatectomy. Clinical Cancer Research , 11:6889-6894.

102.          Do, K-A, Mueller P, Tang F. A nonparametric Bayesian mixture model for gene expression (2005). Journal of the Royal Statistical Society, Series C - Applied Statistics , 54(3):1-18.

103.          Leibovici D, Kamat AM, Do K-A , Pettaway CA, Ng CS, Evans RB, Rodrigu ez-Bigas M, Skibber J, Wang X, Pisters LL (2005). Transrectal ultrasound versus magnetic resonance imaging for detection of rectal wall invasion by prostate can cer. Prostate , 62(1): 101-104.

104.          Cho JH, Troncoso P, Do K-A , Rago C, Wang X, Tsavachidis S, Medeiros LJ, Spurgers K, Logothetis C, McDonnell TJ. Combined laser capture microdissection and micro-serial analysis of gene expression (LCM-microSAGE) from human tissue samples (2005). Modern Pathology , 18(4):577-584.

105.          Wierda WG, O'Brien S, Wen S, Faderl S, Guillermo G-M, Thomas D, Do K-A , Cortes J, Koller C, Beran M, Ferrajoli A, Giles FJ, Lerner S, Albitar M, Kantarjian H, Keating M (2005). Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of Clinical Oncology, 23(18):9 pages.

106.          Do, K-A , Johnson MM, Lee JJ, Wu XF, Dong Q, Hong WK, Khuri FR, Spitz MR (2005). A comprehensive study of the longitudinal effects of smoking relative to development of secondary primary tumors in patients with upper aerodigestive tract cancers (39 pages). To appear in Focus on Smoking and Health Research , Nova Science.

107.          Do, K-A , Johnson MM, Lee JJ, Wu XF, Dong Q, Hong WK, Khuri FR, Spitz MR (2004). A longitudinal study of smoking patterns relative to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract cancers. Cancer , 101(12):2837-2842.

108.          Assikis VJ, Do K-A , Wen S, Wang X, Cho-Vega JH, Brisbay S, Lopez R, Logothetis C, Troncoso P, Papandreou CN, McDonnell TJ (2004). Clinical and bioma rker correlates of androgen-independent, locally aggressive prostate cancer wit h limited metastatic potential. Clinical Cancer Research , 10(20): 6770--6778.

109.          McLachlan GJ, Do, K-A, Ambroise C. Analysing microarray gene expression data (2004). Wiley, NY.

110.          Giles FJ, Vose JM, Do K-A , Johnson MM, Manshouri T, Bociek G, Bierman PJ, O'brien SM, Kantarjian HM, Armitage JO, Albitar M (2004). Clinical relevance of circulating angiogenic factors in patients with Non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leukemia Research , 28(6):596-604.

111.          Wu X, Zhao H, Do K-A , Johnson MM, Dong J, Hong WK, Spitz MR (2004). Serum insulin growth factor (IGF) and IGF-binding protein levels predict risk of second primary tumors in patients with head and neck cancer. Clinical Cancer Research , 10:3988--3995.

112.          Do, K-A, Aitken J, Green A, Martin NG. Analysis of melanoma onset: assessing familial aggregation by using estimating equations and fitting variance components via Bayesian random effects models (2004). Twin Research, 7(1):98--113.

113.          Jonasch E, Do K-A , Logothetis C, McDonnell TJ (2004). Tissue array applications for target and drug discovery. In Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development, 28 pages. Edited by Prendergast, Wiley.

114.          Pisters LL, Pettaway CA, Troncoso P, McDonnel TJ, Stephens LC, Wood CG, Do K-A , Brisbay SM, Wang X, Hossan EA, Evans RB, Soto C, Fenstermacher MJ, Parker K, Merritt JA, Steiner MS, Logothetis CJ (2004). Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clinical Cancer Research , 10:2587--2593.

115.          Leibovici D, Kamat AM, Do K-A , Pettaway CA, Ng CS, Evans RB, Rodri guez-Bigas M, Skibber J, Wang X, Pisters LL (2004). Transrectal ultrasound ver sus magnetic resonance imaging for detection of rectal wall invasion by prosta te cancer. Online publication, The Prostate 9999:1-4.

116.          Do K-A , Broom BM, Wen S (2003). GeneClust. In The analysis of gene expression data: Methods and software, pp 342--361. Edited by Parmigiani G, Garrett ES, Irizarry RA, Zeger SL. Springer, NY.

117.          Kuhnert P, Do K-A (2003). Fitting genetic models to twin data with binary and ordinal outcomes: a simulation study to compare structural equaiton modeling and Bayesian hierarchical models. Behavior Genetics, 33(4), 439-452.

118.          Do K-A et al. (2003). Second primary tumors in patients with upper aerodigetive tract cancers: Joint effects of smoking and alcohol. Cancer Causes and Controls, 14, 131-138.

119.          Wierda WG, Johnson MM, Do K-A , Manshouri T, Day A, O'Brien S, Giles FJ, Kantarjian H, Thomas D, Faderl S, Keating M, Albitar M (2003). Plasma Interleukin-8 level predicts for survival in chronic lymphocytic leukemia. British Journal of Haematology , 120(3), 452--456.

120.          Mintz P, Kim J, Do K-A , Troncoso P, Zinner RG, Hong WK, Logothetis C J, Pasqualini R, Arap W. (2003) Fingerprinting the circulating repertoire of ant ibodies from cancer patients. Nature Biotechnology , 21 (1):57--63.

121.          Soliman AS, Wang X-M, DiGiovanni J, Eissa S, Morad M, Vulimiri S, Mahgoub KG, Johnston DA, Do K-A, Seifeldin IA, Boffetta P, Bondy ML. (2003) Serum organochlorine levels and history of lactation in Egypt. Environmental Re search , 92(2): 110-117.

122.          Do K-A (2002). Biostatistical approaches for modeling longitudinal a nd event time data. Clinical Cancer Research, 8 (8): 2473--2474.

123.          Faderl S, Keating MJ, Do K-A , Liang S-Y, Kantarjian HM, O'Brien S, Garcia-Manero G, Albitar M.(2002). Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia , 16 , 1045--1052.

124.          Sample D, Wargovich M, Fischer SM, Inamdar N, Schwartz P, Wang X, Do K-A , Sinicrope F (2002). A dose-finding study of aspirin for chemopreventoin utilizing rectal mucosal prostaglandin E(2) levels as a biomarker (2002). Cancer Epidemiology Biomarkers and Prevention , 11 , 275--279.

125.          Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ, Mi ntz PJ, Ardelt PU, Yao VJ, Vidal CI, Chen L, Flamm A, Valtanen H, Weavind LM, Hi cks ME, Pollock RE, Botz GH, Bucana CD, Koivunen E, Cahill D, Troncoso P, Bagger ly KA, Pentz RD, Do K-A , Logothetis CJ, Pasqualini R (2002). Steps toward mapping the human vasculature by phage display (2002). Nature Medicine , 8 (2):121--127.

126.          Pu YS, Do K-A , Luo W, Logothetis C, Lin S-H. Enhanced suppression of prostate tumor growth by CEACAM1 gene therapy plus angiogenesis inhibitor TNP- 470. Anti-Cancer Drug , 13 , 1--8.

127.          Sinicrope FA, Hart J, Stephens C, Frazier ML, Half E, Do K-A , Michel assi F (2002). Spontaneous apoptotic rates and P53 expression in sporadic colon carcinomas realtive to hereditary nonpolyposis colorectal cancers. Submitted to International Journal of Cancer .

128.          Manshouri T, Do K-A , Johnson MM, Giles FJ, O'brien S, Cortes J, Thom as D, Kantarjian HM, Keating M, Albitar M (2002). Soluble CD52 in the plasma of patients with chronic lymphocytic leukemia and its influence on CAMPATH-1H therapy. Lancet . In press.

129.          Wayne JD, Lauwers GY, Ikai I, Doherty DA, Belghiti J, Yamaoka Y, Regimbea u JM, Nagorney DM, Do K-A , Ellis LM, Curley SA, Pollock RE, Vauthey JN (2 002). Preoperative predictors of survival after resection of small hepatocellular carcinomas. Annals of Surgery , 235(5): 722--730.

130.          Vauthey J-N, Abdalla EK, Doherty DA, Gertsch P, Loyer EM, Fenstermacher MJ , Lerut J, Materne R, Wang X, Encarnacion A, Herron D, Mathey C, Ferrari G, Charnsangavej A, Do K-A , Denys A (2002). Body surface area and body weight predict total liver volume in Western adults. Liver Transplantation, 8 (3): 233-240.

131.          Fizazi K, Prow DM, Do K-A , Wang X, Finn L, Kim J, Daliani D, Papandreou CN, Tu S-M, Millikan RE, Pagliaro LC, Logothetis CJ, Amato RJ (2002) . Alternating dose-dense chemotherapy in patients with poor diagnosis dissemina ted non-seminomatous germ cell tumors. British Journal of Cancer , 86 (10):1555--1560.

132.          Fizazi K, Do K-A , Wang X, Finn L, Logothetis CJ, Amato RJ (2001). A 20% dose reduction of the original CISCA/VB regimen allows better tolerance a nd identical survival rate in good-risk and intermediate-risk disseminated testi cular non-seminomatous germ-cell tumours: Final results of a Phase III randomized trial. Annals of Oncology , 13 (1): 125-134.

133.          Moore RJ, Do K-A , Doherty DA, Chamberlain RM, Khuri FR (2001). Racia l disparity in survival from squamous cell carcinoma of the oral cavity and phar ynx. Ethnicity and Health, 6(3): 165-177.

134.          Do K-A , Broom BM, X-M Wang (2001) Importance bootstrap resampling for proportional hazards regression. Communications in Statistics - Theory and Methods , 30(10):2173-2188.

135.          Faderl S, Kantarjian HM, Do K-A, Liang S-Y, O'Brien S, Manshouri T, Keatin g M, Albitar M.(2002) Profiling of protein expression and its prognostic signif icance in patients with chronic lymphocytic leukemia (CLL). Leukemia , in press.

136.          Bilimoria MM, Lauwers GY, Doherty DA, Nagorney DM, Belghiti J, Do K-A , Ikai I, Yamaoka Y, Vauthey J-N. (2001) Underlying disease, not tumor factors, predicts long-term survival after hepatic resection of hepatocellular carcinoma. Archives of Surgery , 136 (5):528-535.

137.          Chang DW, Langstein HN, Gupta A, De Monte F, Do K-A , Wang X, Robb G (2001) Reconstructive management of cranial base defects following tumor ablatio n, with Discussion. Plastic and Reconstructive Surgery , 107(6):1346- 1357.

138.          Do K-A , Wang X. Bayesian mixed effects models using BUGS to quantify genetic variance components for normal quantitative traits and age at onset in nuclear families (2000). Genetic Analysis Workshop 12, Volume 2: pp 117-12 1.

139.          Do K-A, Broom BM, Kuhnert P et al (2000) Genetic analysis of the age-at-menopause by using estimating equations and Bayesian random effects models. Statistics in Medicine, 19 : 1217-1235.

140.          Kuhnert P, Do K-A , McClure R. Visualising multivariate models with focus on MARS in an epidemiologica l case-control study. Computational Statistics and Data Analysis , 34:371-386.

141.          Vauthey JN, Chaoui A, Do K-A et al (2000) Standardized measurement of the future liver remnant prior to extended liver resection: Methodology and clinical associations. Surgery , 127 :12-19.

142.          Treloar SA, Sadrzadeh S, Do K-A , Martin NG, Lambalk CB (2000) Birth weight and age at menopause in Australian female twin pairs: exploration of the fetal origin hypothesis. Human Reproduction , 15 (1):55-59.

143.          Do K-A, Green A, Guthrie JR et al (2000) A longitudinal study of risk factors for coronary heart disease across the menopausal transition. American Journal of Epidemiology, 151 :584-593.

144.          Brandt ER, Hayman WA, Currie B, Carapetis J, Jackson DC, Do K-A, Good MF (1999). Functional analysis of IgA antibodies specific for a conserved epitope within the M protein of group A streptococci from Australian Aboriginal endemic communities. Int Immunol: 569-576.

145.          Bellamy N, Klestov A, Muirden K, Kuhnert P, Do K-A , O'Gorman L, Martin N (1999). Perceptual variation in categorising individual peripheral joints for the presence or absence of osteoarthritis using a standard homunculus: observations based on an Australian Twin Registry Study of osteoarthritis. Inflammopharmacology, 7 (1): 37-46.

146.          Bellamy N, Tessar P, Walker D, Klestov A, Muirden K, Kuhnert P, Do K-A , O'Gorman L, Martin N (1999). Perceptual variation in grading hand, hip, and knee radiographs: Observations based on an Australian Twin Registry study of osteoarthritis. Annals of Rheumatic Diseases , 58 (12): 766-769.

147.          Pratiwi R, Fletcher LM, Do K-A et al (1999) Linkage disequilibrium analysis in Australian hemochromatosis patients indicates a non-classical pattern and bipartite association with clinical expression. Journal of Hepatology:39-46.

148.          Hickey K, Do K-A, Green A (2000) Smoking and prostate cancer. Epidemiologic Review, 23(1):115-125.

149.          Do K-A, Kirk K (1999) Discriminant analysis of event-related potential curves using smoothed principal components. Biometrics, 55 : 292-301.

150.          Ryan PA, Do K-A , Kay BH (2000) Definition of Ross River Virus Vectors at Maroochy Shire, Australia. J Medical Entomology , 37 :146-152.

151.          Ryan PA, Do K-A , Kay BH (1999) Spatial and temporal analysis of Ross River Virus disease patterns at Maroochy Shire, Australia: Association between human morbidity and mosquito (Diptera: Culicidae) abundance. J Medical Entomology , 36 , 4:515-521.

152.          Treloar SA, Do K-A et al (1999). Predictors of hysterectomy in an Australian twin study. Amer J Obst Gynae, 180 (4):945-954.

153.          Carlstein E, Do K-A, Hall P, Hesterberg T and Kunsch H (1998) Matched-block bootstrap for dependent data. Bernouilli, 4 : 305-328.

154.          Brayne C, Do K-A et al (1998) Is health protective behaviour in adolescents related to personality? A study of sun protective behaviour and the Eysenck Personality Questionnaire (junior version) in Queensland. Personality and Individual Differences, 25 : 889-895.

155.          Khan S, Do K-A et al (1998) Diagnostic value of P53 immunohistochemistry in Barrett's oesophagus: an endoscopic study. Pathology, 30 : 136-140.

156.          Jass JR, Do K-A et al(1998) Morphology of sporadic RER-positive colorectal cancer. GUT, 42 : 673-679.

157.          Wright K, Wilson PJ, Kerr J, Do K-A et al (1998) Frequent loss of heterozygosity and three critical regions on the short arm of chromosome 8 in ovarian adenocarcinomas. Oncogene, 17 : 1185-1188.

158.          Treloar SA, Do K-A, Martin NG (1998) Genetic influences on the age at menopause (Commentary) Lancet, 352 : 1084-1085.

159.          Do K-A, Treloar S et al (1998) Factors predictive of the age at menopause in a large Australian twin study. Human Biology, 70 : 1073-1091.

160.          Do K-A (1998) Review of ``Modelling Longitudinal and Spatially Correlated Data''. Edited by Gregoire, Brillinger, Diggle, Russek-Cohen, Warren, Wolfinger. Aust J Stat: 249-250.

161.          Do K-A (1996) Review of ``Bayesian Data Analysis'' by Gelman A, Carlin JB, Stern HS, Rubin DB. Aust J Stat, 38: 108-109.

162.          Wood ATA, Do K-A and Broom BM (1996) Sequential linearization of empirical likelihood constraints with application to U- statistics. Journal of Computational and Graphical Statistics, 5 : 365-385.

163.          Do K-A (1995). A numerical study of the matched-block bootstrap for dependent data. (Proceedings of the 27th Symposium on the Interface of Computing Science and Statistics, Pittsburgh, Pennsylvania, June 21-24, 1995: 425-429.

164.          Do K-A (1994) Review of ``Efficient and adaptive estimation for semiparametric models'' by Bickel PJ, Klaassen CAJ, Ritov Y, Wellner JA. Biometrics: 50 : 1227.

165.          Do K-A (1994) Review of ``Large sample methods in statistics: An introduction with applications'' by Sen PK, Singer JM. Aust J Stat: 250-251.

166.          Chen Z, Do K-A (1994). Bootstrap method with saddlepoint approximations and importance resampling. Statistica Sinica, 4: 407-421.

167.          Booth JG, Do K-A(1994) Simple and efficient methods for constructing bootstrap confidence intervals . Computational Statistics, 8: 333-346.

168.          Do K-A, Hall P(1992). Distribution estimation using concomitants of order statistics, with application to Monte Carlo simulation for the bootstrap. Journal of the Royal Statistical Society, Series B, 54: 1-14.

169.          Chen Z, Do K-A (1992). Importance resampling for the smoothed bootstrap. J. Statist. Comp. & Sim., 42. 107-124.

170.          Tridgell A, Millar B, Do K-A (1992) Alternative pre-processing techniques for discrete Hidden Markov model phoneme recognition. {Proceedings of the 1992 International Conference on Speech Recognition, Alberta, Canada.

171.          Do K-A, Kokic P (1992) Bootstrap confidence interval estimation for model-based surveys. Proceedings of the 24th Symposium on the Interface of Computing Science and Statistics, College Station, Texas, March 18-21, 1992: 511-515.

172.          Do K-A, Hall P(1991). On importance sampling for the bootstrap. Biometrika, 78: 161-167.

173.          Do K-A(1991). A simulation study of balanced and antithetic bootstrap resampling methods. J. Statist. Comp. & Sim., 40: 153-166.

174.          Do K-A (1991) Quasi-random resampling for the bootstrap. Proceedings of the 24th Symposium on the Interface of Computing Science and Statistics, Seattle, Washington, April 21-24, 1991: 297-300.

175.          Do K-A, Hall P(1991). Quasi-random resampling for the bootstrap. Statistics and Computing, 1: 13-22.

176.          Powell BL, Craig JB, Kute TE, Lyerly ES, Gregory BW, Do K-A, Contento MM, Capizzi RL (1990) Correlation of the proliferative index of residual leukemia with outcome in patients treated with sequential high dose ara-C and asparaginase. Leukemia, 4 : 316-320.

177.          Weber SF, Peacock JE, Do K-A, Cruz JM, Powell BL, Capizzi R (1990). Interaction of granulocytopenia and construction activity as risk factors in nosocomial invasive filamentous fungal disease in patients with hematologic disorders: potential role of high-efficiency particulate air filtrating during construction activity. Infection Control and Hospital Epidemiology, 11 : 235-242.

178.          Do K-A (1990) A sequential combination of truncated and censored sampling with recapture debugging. Statistics Research Section Technical Report CSTR-023-90, ANU.

179.          Do K-A (1990) On recapture debugging for estimation of population size and confidence bounds. Statistics Research Section Technical Report CSTR-012-90, ANU.

180.          Do K-A, Solomon HS (1986). A simulation study of Sylvester's problem in three dimensions, Journal of Applied Probability, 23 : 509-513.

181.          Do K-A, McLachlan GJ (1984). Estimation of mixing proportions: a case study, Journal of the Royal Statistical Society, Series C, 33 : 134-140.